Aldeyra Therapeutics, Inc. (ALDX) is a Biotechnology company in the Healthcare sector, currently trading at $1.79. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 3 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of ALDX = $414,729,000.00 (+23169217777.1% from the current price, the stock appears undervalued). Analyst consensus target is ALDX = $7 (+291.1% upside).
Valuation: ALDX trades at a trailing Price-to-Earnings (P/E) of -2.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Net income is $34M (loss), growing at +9.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $16M against $44M equity (Debt-to-Equity (D/E) ratio 0.35, conservative). Current ratio is 2.58 (strong liquidity). Debt-to-assets is 21.6%. Total assets: $72M.
Analyst outlook: 18 / 19 analysts rate ALDX as buy (95%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 65/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).
